Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Lancet Oncol. 2018 Feb 20;19(4):549–561. doi: 10.1016/S1470-2045(18)30102-5

Figure 2. Progression-free survival of patients from the training cohort, according to the predictor score.

Figure 2

Kaplan-Meier estimates of progression-free survival in randomized patients of the training cohort, since the time of randomization in PRIMA trial. An optimal threshold was set to separate patients into high- (n=47, 35% of the patients, red curve) and low-risk (n=87, 65% of the patients, blue curve) groups with significantly different outcomes (p<0.0001, log rank test). The 5-year PFS rates were 26% (95%CI: 16-43) and 73% (95%CI: 64-83) for the high-and low-risk groups, respectively. For each time point the number of patients at risk and (number of patients censored) are indicated.

Abbreviations: PFS: progression-free survival.